Background/Aims: Poly r(C) binding protein (PCBP) 1 or heterogeneous ribonucleoprotein (hnRNP) E1 is a RNA binding protein functional in multiple biological processes. In prostate cancer (PCa), PCBP1 loss was shown to be involved with increased stemness in PCacells; however,the underlying mechanism remains unclear. Method: The role of PCBP1 in prostate tumor formationwas determined by xenograft assays. Immunoprecipitationand mass spectrometry were performed to find the pathways altered after PCBP1 knockdown. Cell proliferation, migration, invasion, and soft agar colony formationassays and xenograft assays were used to determine the role of target protein pathogenesis regulation and formation of PCa. QRT-PCR was performedto quantify relative mRNA expression. Results: The expression of mitogen activated protein kinase 1 (MAPK1) or extracellular signal regulated kinase 2 (ERK2) was increased following PCBP1 loss. Attenuation of MAPK1 inhibited in vitro and in vivo tumorigenicity and metastasis in PCa cell line, PC3. Overexpression of MAPK1 in the PC3 cells increased the tumorigenicity and metastasis. Analysis of PCBP1 and MAPK1 mRNA levels in 25 PCa patients compared to tumor-adjacent normal tissue confirmed an inverse correlation between PCBP1 and MAPK1 expression. Conclusions: PCBP1 can act as a suppressor of tumor in prostate epithelial cells by inhibiting MAPK1 expression.
Introduction
Prostate cancer (PCa) is one of the major causes of cancer mortality. In the last few decades, PCa has exhibited steady progress (World Health Organization, 2012). Although research advances has been made, little is known about the underlying pathogenic mechanisms of the generation and maintenance of cancer stem cells which potentiate tumor recurrence and metastasis [1] [2] [3] [4] .
Recently studies has shown that the RNA binding protein, poly r(C) binding protein (PCBP)1 also calledheterogeneous nuclear ribonucleoprotein (hnRNP) E1 is central to maintenance of stemness in prostate cancer cells [5] . It was shown that there is progressive loss of PCBP1 protein expression after TGF-β treatmentusing LNCaP and DU145 prostate cancer cells, which in turn contributes to the CD44 +
CD24
-CD133 + prostate stem cells enrichment and maintenance [5] . However, the precise mechanism regulating theloss of PCBP1 expression is not known.
We thus decided to adapt a prospective way of identifying changes in gene product postloss of PCBP1 expression and whether such changes contribute to prostate tumor formation and metastatic progression. Our experiments show that enforced loss of PCBP1 expression causes upregulation of mitogen-activated protein kinase 3 (MAPK3) along with other genes. In addition, our experiments show that MAPK3 is central to tumorigenesis and metastatic progression in PCa.
Materials and Methods

Cell lines, mouse handling, and reagents
Thestudy was performed strictly according to the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol of animal experiments was approved by the Committee on the Ethics of Animal Experiments of Affiliated Hospital of Jining Medical University. Sodium pentobarbital was used to anesthetize the animal when all surgery was performed.To minimize suffering, all efforts were made. PC3 and CosM6 cell lines were obtained from American Type Culture Collection (ATCC;Manassas,VA, USA). PC3 and CosM6 cells were culturedin DMEM culture medium supplemented with 10% fetal bovine serum, and 10 ml/L of 100 × antibiotic-antimycotic solution. All cells were maintained at 37°C in a humidified atmosphere which contained 5% CO 2 .
Tissue samples, processing, and ethical considerations
Fresh-frozen and paraffin-embedded prostate cancer tissue specimens and corresponding adjacent normal prostate tissue samples were obtained from 25 Chinese patients at the Affiliated Hospital of Jining Medical University between 2014 and 2015. All cases were included post review by pathologist and only where complete clinical pathology and follow-up data was available. The study protocol was approved by the Institutional Review Board of the Affiliated Hospital of Jining Medical University, China. Freshly harvested samples were immersed in RNAlater (Life Technologies, Shanghai, China) before snap freezing within 30 minutes post-surgery and stored in liquid nitrogen until further use.
Plasmid constructs
For shRNA transfection, PC3 or CosM6 cells were transfected with pGIPZ-PCBP1 shRNA (OriGene, Rockville, MD, USA)or pGIPZ-GLB1, or PC3 cells with pGIPZ-MAPK1(Origene) using Lipofectamine LTX transfection reagent (Life Technologies, Shanghai, China). To obtain the stable transfection cells, puromycin was used to select the post-transfection cells. The stable transfection cells were collected and used for indicated downstream experiments. Human MPAK1 plasmid in pCMV6-AC-GFP backbone was obtained from Origene. According to the manufacturer's instructions,the Lipofectamine LTX reagent (Life Technologies, Shanghai, China) was used to transfect the PC3 cells (4 x 10 5 ) with the MAPK1 construct. Cells were diluted 1:10 after 48h of transfection and subsequently selected with G418 (250 μg/ml) (Teknova, Hollister, CA, USA) for approximately 2 weeks. 
Cell lysis and immunoprecipitation
To perform the immunoblot analysis and immunoprecipitation, Pierce IP lysis buffer (ThermoFisher Scientific, Shanghai, China) was used to lyse the cells. The lysis buffer containedmini protease inhibitor cocktail(Roche Diagnostics, Indianapolis, IN, USA) and phosphatase inhibitor cocktails 2 and 3 (SigmaAldrich Shanghai Trading Co Ltd, Shanghai, China). And Pierce Crosslink Immunoprecipitation kit (ThermoFisher Scientific, Shanghai, China) was obtained to perform immunoprecipitation as per manufacturer's protocolusing either rabbit anti-GFP antibody (Santa Cruz Biotechnology, Shanghai, China).
Mass spectrometry
For mass spectrometry, immunoprecipitated protein containing beads were lysed using NET buffer [50 mmol/L Tris-HCl, (pH 7.4), 150 mmol/L NaCl, 0.1% NP40, 1 mmol/L EDTA, 0.25% gelatin, 0.02% sodium azide, 1 mmol/L phenylmethylsulfonyl fluoride, and 1% aprotinin]. The obtained lysates were centrifuged using15, 000 × g at 4°C for 30 minutes. PBS was used to dialysis of the collected supernatant, 5 mM Tris 2-carboxyethyl phosphine (TCEP) was used to reduce the proteins and 10 mM iodoacetamide was used to alkylate the proteins. Samples were digested with trypsin (Promega) in a 1:50 ratio at room temperature for 12 hours. The Ultra MicroTIP Columns (The Nest Group, Southborough, MA, USA) and theSpeedVac concentrator were used to desalt and dry the peptides. Dried peptides were resolubilized in 20 μL HPLC grade water containing 0.1% formic acid. Thelinear ion trap LTQ mass spectrometer (Thermo Electron, San Jose, CA) equipped with a nanoelectrospray ion source (Thermo Electron) coupled to an Agilent 1100 micro HPLC system carried out the sample analysis. Peptides were loaded with a cooled Agilent autosampler on a 2 cm long pre-column filled with C18 resin (Magic C18 AQ 5 μm; MichromBioresources, Auburn, CA, USA). A linear gradient of 80 minutes from 5% to 40% acetonitrile in H 2 O with 0.1% formic acid was used to separate peptides on a 10 cm long fused silica emitter packed with C18 resin spraying directly into the mass spectrometer at a flow rate of 0.5 µl/minute. The MS instrument was operated in positive ion mode. To acquire one MS scan followed by three collision induced dissociation MS/MS scans, the data-dependent acquisition mode was set. The MS full scans were recorded over a mass range of 400-1600 m/z. Dynamic exclusion was enabled, the repeat count was set to 2 and the exclusion duration to 30seconds. Further MS conditions were set as following: spray voltage 1.95 kV, transfer capillary temperature 230°C, normalized collision energy 35%, activation q 0.25 and activation time 30 milliseconds.
Data analysis
We used ReAdW with default settings to convert the acquired raw files to mzXML files and then the Sequest search algorithm was chosen to search against the monkey IPI database version 3.26. The Sequest search parameters contained the static modification of cysteine +57.02 Da, at least one tryptic terminus and one missed cleavage was allowed. To estimate the false discovery rate in the datasets,the data were further processed using the Trans-Proteomic Pipeline TPP including PeptideProphet and ProteinProphet. A protein probability of 0.5 was set as a cutoff corresponding to a false discovery rate of approximately 5%. The algorithm SignalPwas used to annotate the protein liat for secreted proteins. UniProt database and literature search was chosen to further manually curatefor secreted proteins. Functional annotation was assigned using the PANTHER Classification system. Relative enrichment or depletion in the shRNA-PCBP1 population was determined relative to shRNA-GLB1 cells and data was normalized using multiple housekeeping gene products. A fold-change (increase or decrease) above 5 was considered significant.
Cell proliferation assay
Mitochondrial colorimetric assay (MTT assay, Sigma-Aldrich, St. Louis, MO) was used to quantitate cell proliferation as per the manufacturer's recommendations. Results were represented by relative optical density (OD) and expressed as mean ± standard deviation.
In vitro migration assay PC3 cells stably expressing shRNA-MAPK1or GLB1were cultured without serum overnight, and then treated with mitomycin-C.All the cells were trypsinized and transferred into the upper chamber (5 × 10 4 / well) of the Transwell (8 µm pore size; BD Bioscience). The medium supplemented with 5%FBS was served as thechemoattractant in the lower chamber. Then the 3% glutaraldehyde and crystal violet were used to 
In vitro invasion assay
To determine cells invasion ability,we carried out amodified in vitro Boyden chamber invasion assay with Matrigel-coated Transwell chambers (8 μm pore size). PC3 cells stably expressing shRNA-MAPK1or GLB1 were cultured without serum overnight, and then treated with mitomycin-C beforethe cells were trypsinized andtransferredinto the upper chamber (5 × 10 4 /well) to rehydrated Matrigel-coated inserts (BioCoatMatrigel Invasion Chamber; Becton Dickinson) and placed in 24-well companion trans plates with DMEM and 5% FBS (chemoattractant) to induce invasive cells to digest the coating and invade through the pores to the trans side. After 24 hours, the cells and Matrigel in the upper chambers were removed, and 3% glutaraldehyde and crystal violet were used to fix and stained the cells in the bottom trans chambers respectively. The cells stained by crystal were counted with an inverted microscope in 5 randomly different fields. All theinvasion assayexperiments were performed in triplicates and repeated three individual times.
Soft agar colony formation assay
) were re-suspended in 3ml of DMEM containing 0.3% agar and layered in 60 mm dishes containing6 ml of 0.5% agar beds. Cells were subsequently grown for 2weeks before being photographed and quantified. The criterionof positive colonies was the diameter greater than 50 μm.
Xenograft assays
For xenograft assays, six-week-old female p53 -/-mice (n=3 per group) were sub-cutaneousinjected 10 6 indicated cells at hind flank of mice. Tumor formation and metastasis of mice were assessed weekly up to 25 days using in vivo bioluminescence imaging using an IVIS Imaging System (IVIS imaging system 200, Xenogen Corporation, PerkinElmer, Waltham, USA) fitted with an ultrasensitive CCD camera.
RNA extraction and quantitative real time polymerase chain reaction (qRT-PCR)
Total RNA was tissue specimens using Trizol reagent. Real-time polymerase chain reaction (PCR) was performed using TaqMan Gene Expression probes (Life Technology, Beijing, China). GAPDH (TaqMan Assay ID: Hs02758991_g1) was used as an internal control for assessing MAPK1 and PCBP1 expression level. Data was normalized to GAPDH mRNA expression and analyzed by the -ΔΔCt method.
Statistical analysis
Two-tailed Student's t testwas used to ascertain the Statistical significance between two comparator groups. All experimentaldata were presented as mean ± standard error of mean (SEM). The criterion of indicating statistical significance is the Pvalue < 0.05.
Results
To understand the role of PCBP1 in prostate tumor formation, we initially did xenograft assays with PC3 cells, stably expressing either a GFP-tagged shRNA targeting beta-galactosidase (GLB1) or PCBP1. Whereas, PC3/shRNA-GLB1 cells formed small detectable tumors by Day 25 (Fig. 1A) , the PC3/shRNA-PCBP1 cells formed robust tumors and metastatic lesions by day 25 (Fig. 1B) . This indicated that lack of PCBP1 expression promoted both tumorigenesis and metastatic progression in prostate cancer, suggestive of PCBP1 functioning as a tumor suppressor in normal prostate epithelial cells.
We next wanted to determine the pathways that are altered in the PCBP1 knockdown cells. For the same, we made stable pools of the shRNA-GLB1 and shRNA-PCBP1 cells in the CosM6 cells. Since the shRNAs were in the pGIPZ vector which also made GFP, cell lysates made from the aforementioned cells were immunoprecipitated using anti-GFP antibody ( Fig. 2A) . Immunoprecipitated products were processed and analyzed by mass spectrometry (Fig. 2B, C) . Differentially expressed proteins showing at least 5 folds difference between the two cell types was analyzed (Fig. 3) . Supplementary Table 1 Supplementary Table 3 .
To further determine the role of MAPK1 in PCa pathogenesis regulation, we generated stable clones of PC3 expressing shRNA targeting MAPK1 and tested them in in vitro assays for proliferation, migration, invasion, and soft agar colony formation. As shown in Fig. 4 , silencing of MAPK1 expression in PC3 cells significantly inhibited cell proliferation (91.3 ± 3.4% in PC3/shRNA-GLB1 versus 39.7 ± 19.01% in PC3/shRNA-MAPK1, p = 0.0081) and colony formation (92 ± 3% in PC3/shRNA-GLB1 versus 37 ± 11% in PC3/shRNA-MAPK1, p = 0.0056), both properties associated with tumorigenic potential of cells. In addition, silencing of MAPK1 expression in PC3 cells significantly attenuated in vitro migration (59.8 ± 31.27% in PC3/shRNA-GLB1 versus 24.2 ± 7.16% in PC3/shRNA-MAPK1, p = 0.009) and invasion (78.5 ± 1.4% in PC3/shRNA-GLB1 versus 38.7 ± 12.37% in PC3/shRNA-MAPK1, p = 0.083), both properties associated with metastatic dissemination of primary tumor (Fig.  4) .Our results showed that MAPK1down-regulation is perhaps important to tumorigenicity and metastatic progression of these cells.
In order to understand the in vivo role of MAPK1 in formation of prostate tumor, we alsodid xenograft assays with PC3 cells, stably expressing either a GFP-tagged shRNA targeting beta-galactosidase (GLB1) or MAPK1, or overexpressing MAPK1. Whereas, PC3/ shRNA-GLB1 cells formed numerous small tumors and metastatic lesions by Day 25 (Fig.  5A) , the PC3/shRNA-MAPK1 cells did not form any tumors at all (Fig. 5B) . On the other hand, the PC3/MAPK1 overexpression cells formed significantly bigger tumors and metastatic lesions by day 25 (Fig. 5C) . Cumulatively, this indicated that MAPK1 can potentiate both 
Discussion
It is widely knownthat stem/progenitor cells are responsible for chemoresistance [6] [7] [8] and that lack of PCBP1 expression might be one of the central pathways underlying acquired chemoresistance [5] . Thus proto-oncogenes up-regulated as a result of repression of PCBP1 expression might be an attractive target to circumvent chemoresistance in patients with prostate cancer.
Given that PCBP1 expression was being knocked down, this precluded us from doing an immunoprecipitation using anti-PCBP1 antibody. The converse strategy of overexpressing PCBP1 would be counter intuitive as any proto-oncogene that is normally suppressed by PCBP1 would be further suppressed in such cases and would avoid detection. Hence, we rationalized to perform an immunoprecipitation using anti-GFP antibody. The pGIPZ shRNA construct has constitutive GFP expression and hence leveraged a tool that could be successfully used to query the mechanistic pathway in PCBP1 knockdown cells. The reason CosM6 cells was used was for robust protein synthesis and easy subculturing, providing us enough starting material for the immunoprecipitation and mass spectrometry analysis.
Our results cumulatively show that MAPK1 is up-regulated following loss of PCBP1. The MAPK pathway is well-known to be associated with tumor progression [9] and its upregulation is associated with prostate cancer too [10] . In fact, it has been shown that miR-378 which targets MAPK1 is down-regulated in PCa cells [11] . In addition it has been shown that the Her2/Raf-1/MAPK/AP-1 axis promotes castrate resistant prostate cancer [10] . Both p38 MAPK and MAPK1 has been shown to regulate E-cadherin-mediated phenotypic switching in prostate cancer [12] . ERK2 was shown as an independent prognostic marker for prostate cancer [13] . In fact, ERK2 along with the Y-box binding protein was shown to promote prostate cancer progression [13] . Our findings thus added another layer of regulation for MAPK1 by the RNA-binding protein PCBP1.
In pancreatic, ovarian and breast cancer cell line,PCBP1 has been shown to regulate the stability of the pro-oncogenic p63 transcript [14] . In addition, repression of PCBP1 it has been shown thatthe repression of PCBP1 can up-regulate translation of genes and long non-coding RNA which is required for epithelial to mesenchymal transition and metastasis in somecancers, including breast, lung, and gastric cancer [15] [16] [17] [18] [19] . In addition, inactivating mutations in PCBP1 has been identified in Burkitt lymphoma [20] . Thus it might be possible that down-regulation of PCBP1 represents a central point, inhibition of which is a common mechanism to increase stemness and mesenchymal cell formation in a context dependent fashion, as observed by us in the current study and the others [14] [15] [16] [17] [18] [19] [20] . 
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